Drug Profile
Cobomarsen - Viridian Therapeutics
Alternative Names: MRG-106Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator miRagen Therapeutics
- Developer Viridian Therapeutics
- Class Antineoplastics; MicroRNAs
- Mechanism of Action MicroRNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Cutaneous T-cell lymphoma
- No development reported Adult T-cell leukaemia-lymphoma; Amyotrophic lateral sclerosis; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Adult T cell leukaemia-lymphoma(Monotherapy, Second-line therapy or greater) in USA (IV)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Adult T cell leukaemia-lymphoma(Monotherapy, Second-line therapy or greater) in USA (SC)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Monotherapy, Second-line therapy or greater) in USA (IV)